Quarter Period Statement Of Income

Daito Pharmaceutical Co., Ltd. - Filing #7341852

Concept 2023-06-01 to
2024-02-29
2022-06-01 to
2023-02-28
Quarter period statement of income
Statement of income
Net sales
34,662,000,000 JPY
34,570,000,000 JPY
Cost of sales
27,367,000,000 JPY
26,608,000,000 JPY
Gross profit (loss)
7,295,000,000 JPY
7,962,000,000 JPY
Selling, general and administrative expenses
4,190,000,000 JPY
3,856,000,000 JPY
Selling, general and administrative expenses
Operating profit (loss)
3,105,000,000 JPY
4,106,000,000 JPY
Non-operating income
Interest income
0 JPY
3,000,000 JPY
Dividend income
64,000,000 JPY
57,000,000 JPY
Non-operating income
106,000,000 JPY
79,000,000 JPY
Non-operating expenses
Interest expenses
22,000,000 JPY
11,000,000 JPY
Non-operating expenses
88,000,000 JPY
107,000,000 JPY
Ordinary profit (loss)
3,122,000,000 JPY
4,077,000,000 JPY
Extraordinary income
Extraordinary income
326,000,000 JPY
JPY
Extraordinary losses
Extraordinary losses
9,000,000 JPY
81,000,000 JPY
Profit (loss) before income taxes
3,440,000,000 JPY
3,996,000,000 JPY
Income taxes
1,170,000,000 JPY
1,376,000,000 JPY
Profit (loss)
2,270,000,000 JPY
2,619,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.